Influence of nasal highflow-therapy on oxygenation index compared with lowflowoxygen-therapy in patients with comunitiy aquired pneumonia on peripheral ward

Influence of nasal highflow-therapy on oxygenation index compared with lowflowoxygen-therapy in patients with comunitiy aquired pneumonia on peripheral ward - INHALATION

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00023528

Enrollment

Registered

2020-12-14

Start date

2021-04-26

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community acquired pneumonia J12

Interventions

Group 1: highflowoxygen-therapy Patients will be stratified by oxygenation index into two groups (oxygenation index 100-200 bzw. 200-300) . 1-2 h after changing therapy, bloodgases will be controlle

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - age >18Jahre - diagnosis of community aquired pneumonia (conilidation chest-X-ray or CT-scan) - mild to moderate disturbance of oxygenation (oxigenation index 100-300)

Exclusion criteria

Exclusion criteria: - oxygenation index < 100 - COVID19-pneumonia - pregnance - age < 18 - missing of patients consent

Design outcomes

Primary

Measure	Time frame
oxygenation index d 3 after study enrollment	—

Secondary

Measure	Time frame
- sociodemographic data o gender o year of birth - Patient data o height o weight o BMI - risc factors o CRB-65-Score o Q-SOFA-Score o smoking o dysphagia - pulmonary disease o emphysema o COPD o Asthma o ILD - immunosuppression o drug induced iimmunosuppression o habituell immunosuppression - lungfunction o FVC (absolute/% normal) o FEV1/VC o FEV1 (absolute/% normal) - symptomas o dyspnoea Borgscala (1-10) --time of recruiting, day 1,2 3 and before discharge - pO2/pCO2, pH -- at time of admission, day 1,2,3 and before discharge, furthermore 1-2 h after changing of therapy - therapy o Highflow: ? rate (l/min) ? fiO2 ? temperature (°C) ? utilisation (h) o lowflow ? application form ? l/min - hospitilisation data o ICU o time of Ventilation o length of stay o mortality - microbiologic data concomitant diseases	—

Measure

Time frame

- sociodemographic data o gender o year of birth - Patient data o height o weight o BMI - risc factors o CRB-65-Score o Q-SOFA-Score o smoking o dysphagia - pulmonary disease o emphysema o COPD o Asthma o ILD - immunosuppression o drug induced iimmunosuppression o habituell immunosuppression - lungfunction o FVC (absolute/% normal) o FEV1/VC o FEV1 (absolute/% normal) - symptomas o dyspnoea Borgscala (1-10) --time of recruiting, day 1,2 3 and before discharge - pO2/pCO2, pH -- at time of admission, day 1,2,3 and before discharge, furthermore 1-2 h after changing of therapy - therapy o Highflow: ? rate (l/min) ? fiO2 ? temperature (°C) ? utilisation (h) o lowflow ? application form ? l/min - hospitilisation data o ICU o time of Ventilation o length of stay o mortality - microbiologic data concomitant diseases

—

Countries

Germany

Contacts

Public ContactAchim Grünewaldt

Universitätsklinikum FrankfurtMedizinische Klinik 1Pneumologie/Allergologie

achim.gruenewaldt@kgu.de069 6301 4121

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026